Cargando…
Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
RationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions. Here, we present a case of idiopathic multicentric Castleman disease in the eighth decade of life. Pati...
Autores principales: | Chrysochoou, Stamatios, Kreft, Andreas, Schneider, Eberhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986409/ https://www.ncbi.nlm.nih.gov/pubmed/35399163 http://dx.doi.org/10.1155/2022/1840589 |
Ejemplares similares
-
Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
por: Sitenga, Jenna, et al.
Publicado: (2018) -
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022) -
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021) -
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022) -
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)